Sacubitril/Valsartan to Reduce Secondary Mitral Regurgitation

Wilfried Mullens^{1

2}, Pieter Martens^{1

3}

Affiliations

¹ Department of Cardiology, Ziekenhuis Oost-Limburg, Genk, Belgium (W.M., P.M.).
² Biomedical Research Institute, Faculty of Medicine and Life Sciences, Hasselt University, Diepenbeek, Belgium (W.M.).
³ Doctoral School for Medicine and Life Sciences, Hasselt University, Diepenbeek, Belgium (P.M.).

Editorial

Wilfried Mullens et al. Circulation. 2019.

. 2019 Mar 12;139(11):1366-1370.

doi: 10.1161/CIRCULATIONAHA.118.038135.

Wilfried Mullens^{1

2}, Pieter Martens^{1

3}

¹ Department of Cardiology, Ziekenhuis Oost-Limburg, Genk, Belgium (W.M., P.M.).
² Biomedical Research Institute, Faculty of Medicine and Life Sciences, Hasselt University, Diepenbeek, Belgium (W.M.).
³ Doctoral School for Medicine and Life Sciences, Hasselt University, Diepenbeek, Belgium (P.M.).

No abstract available

Keywords: Editorials; guideline; heart failure; heart ventricles; mitral valve insufficiency.

Comment on

Angiotensin Receptor Neprilysin Inhibitor for Functional Mitral Regurgitation.
Kang DH, Park SJ, Shin SH, Hong GR, Lee S, Kim MS, Yun SC, Song JM, Park SW, Kim JJ. Kang DH, et al. Circulation. 2019 Mar 12;139(11):1354-1365. doi: 10.1161/CIRCULATIONAHA.118.037077. Circulation. 2019. PMID: 30586756 Clinical Trial.